Opdivo, Opdualag Still Benefits Patients With Melanoma at 2 Years
Source: Cure Today, June 2023
After two years of follow-up, patients with advanced melanoma treated with Opdivo and Opdualag continued to obtain a survival benefit compared with Opdivo alone.
Patients with previously untreated, unresectable or metastatic melanoma continued to derive a benefit after two years from treatment with Opdivo (nivolumab) plus Opdualag (relatlimab) compared with Opdivo alone, according to recent trial data.
These findings were presented by Dr. Hussein A. Tawbi at the 2023 ASCO Annual Meeting.